Search results
Dec 14, 2023 · Pfizer’s $43 billion acquisition of Seagen is in the books, as it becomes the largest M&A transaction in the biopharma industry since AbbVie snatched up Allergan for $63 billion in 2019. The ...
Enfortumab vedotin. Enfortumab vedotin-ejfv (PADCEV®) is a first-in-class antibody–drug conjugate (ADC) directed against Nectin-4, a protein located on the surface of cells that is highly expressed in bladder cancer. 1,2. Nonclinical data suggest the anticancer activity of enfortumab vedotin is due to binding to Nectin-4–expressing cells ...
Sep 22, 2023 · A combination of cancer drugs from Seagen and Merck & Co. has shown early success in a large clinical trial, results that help confirm the pairing’s ability to treat a wide range of bladder cancer patients. The trial has enrolled around 1,000 participants who have urothelial cancer that’s grown or spread to other parts of the body, and who ...
Indication. TUKYSA is a kinase inhibitor indicated: in combination with trastuzumab and capecitabine for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.
Brentuximab vedotin (ADCETRIS®) targets CD30 using our proprietary antibody–drug conjugate (ADC) technology. CD30 is found on the surface of most classical Hodgkin lymphoma (HL) cells and in several types of non-Hodgkin lymphoma, but not commonly found on healthy cells. This ADC therapy uses a linker system that is designed to be stable in ...
Tucatinib (TUKYSA®) is an oral medicine that is a tyrosine kinase inhibitor of the HER2 protein, a protein that contributes to cancer cell growth. 1,2 HER2 is overexpressed in multiple cancers, including breast, colorectal, and gastric cancers. 3. In preclinical in vitro studies, TUKYSA inhibited phosphorylation of HER2 and HER3, resulting in ...
Mar 13, 2023 · Seagen's four commercial products are Adcetris, Padcev, Tukysa and Tivdak, which together generated $1.7 billion last year. The foursome will bring in $8 billion annually by 2030, Pfizer estimates ...
